Show simple item record

dc.contributor.authorButler-Henderson, Kerryn Ann
dc.contributor.supervisorProf. Andy Lee
dc.contributor.supervisorDr Nat Lenzo
dc.contributor.supervisorProf. Roger Price
dc.date.accessioned2017-01-30T10:21:31Z
dc.date.available2017-01-30T10:21:31Z
dc.date.created2014-07-30T03:13:13Z
dc.date.issued2014
dc.identifier.urihttp://hdl.handle.net/20.500.11937/2414
dc.description.abstract

The use of a hand-held positron emission tomography (PET) probe during breast surgery can potentially reduce the rate of second operations, having a number of implications. The PET probe tested in ductal carcinoma in situ (DCIS) surgery demonstrated to be 96.5% accurate when compared to pathology. This research examines the current technology available, the epidemiology of DCIS in Western Australia, testing of the radiopharmaceutical used with the probe and the PET probe itself.

dc.languageen
dc.publisherCurtin University
dc.titleRadiopharmaceuticals and the PET probe in the detection of Ductal Carcinoma in situ of the breast
dc.typeThesis
dcterms.educationLevelPhD
curtin.departmentSchool of Public Health
curtin.accessStatusOpen access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record